% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Heining:131583,
      author       = {C. Heining$^*$ and P. Horak$^*$ and S. Gröschel$^*$ and H.
                      Glimm$^*$ and S. Fröhling$^*$},
      title        = {[{P}ersonalized oncology].},
      journal      = {Der Radiologe},
      volume       = {57},
      number       = {10},
      issn         = {1432-2102},
      address      = {Berlin},
      publisher    = {Springer},
      reportid     = {DKFZ-2017-06215},
      pages        = {804 - 811},
      year         = {2017},
      abstract     = {Innovative next generation sequencing (NGS) technologies
                      and comprehensive sequencing investigations in large patient
                      cohorts have paved the way for very promising personalized
                      treatment strategies based on the molecular characteristics
                      of individual tumors.Targeted therapies, such as tyrosine
                      kinase inhibitors, antibodies and modern immunotherapeutic
                      approaches are well established as monotherapy and
                      combination therapy for many hematological and oncological
                      malignancies.A plethora of innovative therapies targeting
                      various components of intracellular signaling cascades and
                      effective mechanisms against oncogenes as well as the
                      availability of NGS technologies enable personalized cancer
                      treatment based on the molecular profiles of individual
                      tumors and genetic stratification, within clinical
                      trials.Comprehensive genetic approaches including cancer
                      gene panel sequencing, whole exome, whole genome and
                      transcriptome sequencing are carried out to a varying extent
                      and particularly in the academic setting.Principally, a
                      comprehensive characterization of tumors in addition to DNA
                      and RNA sequencing that also incorporates epigenetic,
                      metabolomic, and proteomic alterations would be desirable. A
                      comprehensive clinical implementation of integrative,
                      multidimensional genetic typing is, however, currently not
                      possible.It remains to be demonstrated whether these
                      approaches will translate into significantly better outcomes
                      for patients and whether they can be increasingly
                      implemented in the routine diagnostic work-up.The selection
                      of diagnostic tools in individual cases and the extent of
                      genomic analyses in the clinical context, need to take the
                      availability of methods as well as the present clinical
                      situation into account.},
      subtyp        = {Review Article},
      cin          = {G100 / G240},
      ddc          = {610},
      cid          = {I:(DE-He78)G100-20160331 / I:(DE-He78)G240-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:28875369},
      doi          = {10.1007/s00117-017-0297-9},
      url          = {https://inrepo02.dkfz.de/record/131583},
}